ABP 938 for Chorioretinal Vascular Disease

Phase-Based Progress Estimates
Retina Consultants of Texas - Bellaire Retina Center, Bellaire, TXChorioretinal Vascular DiseaseABP 938 - Drug
18 - 99
All Sexes
What conditions do you have?

Study Summary

This trial studies the accuracy of eye injections with a new drug, ABP 938, compared to an existing drug, aflibercept.

Eligible Conditions
  • Chorioretinal Vascular Disease

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Up to 35 Days

Day 35
Number of Successful IVT Injections Utilizing aflibercept
Proportion of Successful IVT Injections Utilizing ABP 938
Up to 35 Days
Number of Non-ocular SAEs
Number of Ocular Adverse Events (AEs)
Number of Serious Adverse Events (SAEs) in the Study Eye

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

ABP 938
1 of 2
1 of 2

Experimental Treatment

48 Total Participants · 2 Treatment Groups

Primary Treatment: ABP 938 · No Placebo Group · Phase 3

ABP 938
Experimental Group · 1 Intervention: ABP 938 · Intervention Types: Drug
Experimental Group · 1 Intervention: Aflibercept · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
ABP 938
Completed Phase 3
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 35 days

Who is running the clinical trial?

AmgenLead Sponsor
1,301 Previous Clinical Trials
1,330,118 Total Patients Enrolled
MDStudy DirectorAmgen
843 Previous Clinical Trials
899,422 Total Patients Enrolled

Eligibility Criteria

Age 18 - 99 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are 18 years old or older, regardless of gender.

Frequently Asked Questions

Is there an upper age limit for potential participants in this research?

"As per the eligibility requirements for this trial, the age range accepted is 18 to 99." - Anonymous Online Contributor

Unverified Answer

What safety precautions are necessary when administering ABP 938 to patients?

"We rate ABP 938's safety at a 3 on the scale of 1-3 due to its Phase 3 status and evidence both for efficacy and multiple rounds of data proving its security." - Anonymous Online Contributor

Unverified Answer

Are there currently any vacancies in this experiment for volunteers?

"Per clinicaltrials.gov, the trial that was initially posted on 1/23/2023 is currently recruiting participants. This information has been recently updated as of 2/10/2023." - Anonymous Online Contributor

Unverified Answer

What is the current tally of facilities conducting this clinical trial?

"There are 4 clinical trial sites that have begun recruiting patients, such as the Bellaire Retina Center in Texas, San Antonio's Retina Centre and The Woodlands' Retinal Consultants of Texas." - Anonymous Online Contributor

Unverified Answer

How many participants are currently enrolled in this research initiative?

"Affirmative. According to the clinicaltrials.gov portal, this medical trial is searching for 48 participants across 4 sites and was initially posted on January 23rd 2023 with a later update occurring on February 10th of that same year." - Anonymous Online Contributor

Unverified Answer

What are the eligibility requirements for participation in this trial?

"The study requires 48 individuals who have chorioretinal vascular disease and are between 18-99 years of age. The key criteria for applicants include signing an approved informed consent form, being male or female over the age of eighteen, and having neovascular age-related [macular degeneration](https://www.withpower.com/clinical-trials/macular-degeneration), diabetic macular edema, macular edema due to retinal vein occlusion or diabetic retinopathy in one eye (with treatment not necessary)." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.